Home › NDC Lookup › RxCUI directory › RxCUI 2730666

Mitapivat 100 MG Oral Tablet [Aqvesme] — RxCUI 2730666

RxNorm drug concept · Semantic branded drug
RxCUI 2730666 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2730666
Official nameMitapivat 100 MG Oral Tablet [Aqvesme]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAqvesme 100 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mitapivat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats certain inherited anemias in adults. Pyrukynd is for hemolytic anemia from pyruvate kinase deficiency. Aqvesme is for anemia from alpha- or beta-thalassemia. Your brand d...
  • Take it by mouth twice a day, with or without food. Swallow the tablet whole and don't split, crush or chew it. If you're 4 hours late or less, take the missed dose. If it's more t...
  • Talk to your prescriber first. With Pyrukynd, stopping suddenly can cause red blood cells to break down quickly, so a gradual taper is usually used. With Aqvesme no taper is needed...
  • Headache and trouble sleeping were the most common in studies of Aqvesme. Men may also have hormone changes, which reversed after stopping in the few men checked. Call your doctor...
📖 Read our full Mitapivat guide →

🕸️ Concept Web — How Mitapivat 100 MG Oral Tablet [Aqvesme] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mitapivat 100 MG Oral Tablet [Aqvesme] RxCUI 2730666

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mitapivat 2594468
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aqvesme 2730661
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mitapivat Oral Tablet 2594472
    • Mitapivat Oral Product 2594470
    • Mitapivat Pill 2594471
    • Mitapivat Oral Tablet [Aqvesme] 2730665
    • Aqvesme Oral Product 2730663
    • Aqvesme Pill 2730664
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mitapivat 100 MG Oral Tablet SCD · 2730660
  • Mitapivat 100 MG SCDC · 2730659
  • Mitapivat Oral Tablet SCDF · 2594472
  • Mitapivat Oral Product SCDG · 2594470
  • Mitapivat Pill SCDG · 2594471

Brand-Name Concepts

  • Mitapivat 100 MG [Aqvesme] SBDC · 2730662
  • Mitapivat Oral Tablet [Aqvesme] SBDF · 2730665
  • Aqvesme Oral Product SBDG · 2730663
  • Aqvesme Pill SBDG · 2730664
  • Aqvesme BN · 2730661

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2730666 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71334-0235-00 4 BLISTER PACK in 1 CARTON (71334-235-00) / 14 TABLET, FILM... AQVESME Agios Pharmaceuticals, Inc. 2025-12-23
Observed labelers: Agios Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.